Pharmacological modulation of the gut microbiota for chronic disease management

Read full text Summarise with VIRAT
Authors: Carlos García Fernández, Elena Martínez Rüiz, Javier Lopez Navarro, Isabel Sánchez Moreno
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The human gut harbors roughly 100 trillion microorganisms whose collective metabolic output rivals that of the liver, yet the pharmacological manipulation of this ecosystem for therapeutic benefit remains in its early stages [1]. This research evaluated four microbiota-modulating interventions-probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT)-against placebo in 248 adults with chronic inflammatory conditions at two Spanish academic hospitals between February 2021 and July 2023. Participants were diagnosed with one or more of type 2 diabetes mellitus, cardiovascular disease, or inflammatory bowel disease, and were randomized to receive 24 weeks of their assigned intervention alongside standard medical therapy. The primary outcome was change in Shannon diversity index measured by 16S rRNA gene sequsencing of fecal samples. FMT produced the greatest microbiota diversity increase, raising the Shannon index from a baseline mean of 3.42 to 5.47 at week 24 (p

Fields of Study & Subjects

Gut microbiota and health Probiotics and Fermented Foods Gastrointestinal motility and disorders

Publication details

Journal / source
International Journal of Pharmacology and Pharmaceutical Research
Volume
8
Issue
2
Pages
08–13
Publication date
1 February 2026
Language
EN